Changes in Hong Kong stocks | Junshi Biotech (01877) rose more than 3%. Both new bispecific antibody drugs plan to launch key phase III clinical studies within the year

The Zhitong Finance App learned that Junshi Biotech (01877) rose more than 3%. As of press release, it had risen 3.07% to HK$17.11, with a turnover of HK$199551 million.

According to the news, on September 14, Junshi Biotech revealed the latest research and development progress of the core innovative drug pipeline at the 2026 semi-annual performance briefing. The company made it clear that the two new bispecific antibody drugs, which have received much attention, plan to launch key phase III clinical studies within 2026. Among them, JS203, a dual-antibody drug targeting CD20/CD3, will officially enter phase III clinical phase; JS207, another dual-antibody drug targeting PD-1/VEGF, is currently in phase II clinical research. It is actively exploring combined drug use with different treatments such as chemotherapy, monoclonal antibodies, and ADC in multiple tumors, and is also expected to begin phase III clinical trials within 2026.